Differences in glycemic control between the treatment arms in cardiovascular outcome trials of type 2 diabetes medications do not explain cardiovascular benefits by Darren K. McGuire, Silvio E. Inzucchi, Odd Erik Johansen, Julio Rosenstock, Jyothis T. George, Nikolaus Marx

Get full text

Cardio/Kidney Composite End Points: A Post Hoc Analysis of the EMPA‐REG OUTCOME Trial by João Pedro Ferreira, Bettina Johanna Kraus, Isabella Zwiener, Sabine Lauer, Bernard Zinman, David H. Fitchett, Audrey Koitka‐Weber, Jyothis T. George, Anne Pernille Ofstad, Christoph Wanner, Faiez Zannad

Get full text

Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA‐REG OUTCOME trial by David Fitchett, Silvio E. Inzucchi, Bernard Zinman, Christoph Wanner, Martin Schumacher, Claudia Schmoor, Kristin Ohneberg, Anne Pernille Ofstad, Afshin Salsali, Jyothis T. George, Stefan Hantel, Erich Bluhmki, John M. Lachin, Faiez Zannad

Get full text

Design and rationale of the EMPA‐VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure by Moritz J. Hundertmark, Olorunsola F. Agbaje, Ruth Coleman, Jyothis T. George, Rolf Grempler, Rury R. Holman, Hanan Lamlum, Jisoo Lee, Joanne E. Milton, Heiko G. Niessen, Oliver Rider, Christopher T. Rodgers, Ladislav Valkovič, Eleanor Wicks, Masliza Mahmod, Stefan Neubauer

Get full text

Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placeb... by Julio Rosenstock, Vlado Perkovic, John H. Alexander, Mark E. Cooper, Nikolaus Marx, Michael J. Pencina, Robert D. Toto, Christoph Wanner, Bernard Zinman, David Baanstra, Egon Pfarr, Michaela Mattheus, Uli C. Broedl, Hans-Juergen Woerle, Jyothis T. George, Maximilian von Eynatten, Darren K. McGuire, CARMELINA® investigators

Get full text